AMOXYTRON CHEWABLE TABLETS

Benefits:

• First-line treatment of bacterial infections

• Broad-spectrum antibacterial effect

• Affects β-lactamase producing strains

• Convenient dosing regimen based on the animal bodyweight

• Easy to use — tablets with fresh meat taste and flavor

Composition and pharmacological properties:

The drug contains amoxicillin in the form of trihydrate and clavulanic acid in the form of potassium clavulanate as active ingredients.

The drug is available in three dosages:

- "Amoxytron chewable tablets 50 mg" containing amoxicillin 40 mg and clavulanic acid 10 mg per tablet;

- "Amoxytron chewable tablets 250 mg containing amoxicillin 200 mg and clavulanic acid 50 mg per tablet;

- Amoxytron chewable tablets 500 mg containing amoxicillin 400 mg and clavulanic acid 100 mg per tablet.

The drug contains: lactose, calcium stearate, hypromellose, potato starch, colloidal silicon dioxide, an additive with the taste and aroma of fresh meat, erythrosine as excipients.

Amoxicillin and clavulanic acid (active ingredients of the drug) provide a broad-spectrum antibacterial effect against most Gram-positive and Gram-negative organisms, including Staphylococcus spp. (including beta-lactamase producing strains), Corynebacterium spp., Streptococcus spp., Clostridium spp., Peptostreptococcus spp., Escherichia coli (including β-lactamase-producing strains), Salmonella spp. (including beta-lactamase producing strains), Pasteurella spp., Klebsiella spp., Proteus spp., Fusobacterium necrophorum, Campylobacter spp.

Amoxicillin is a semi–synthetic antibiotic from the group of penicillins. The mechanism of antibacterial effect of amoxicillin is based on inhibition of the functional activity of bacterial enzymes transpeptidases involved in binding the main component of the cell wall of organisms - peptidoglycan, which leads to a violation of the osmotic balance, destruction and death of the bacterial cell. Amoxicillin is a first-choice drug for symptomatic treatment based on a preliminary diagnosis.

Clavulanic acid irreversibly inhibits intracellular and extracellular β-lactamases and protects the amoxicillin molecule from inactivation under the effect of various β-lactamases produced by bacteria, thereby restoring the sensitivity of bacteria to the bactericidal effect of amoxicillin in concentrations that are easily achieved in animal tissues after drug administration.

After oral administration amoxicillin and clavulanic acid are well absorbed from the gastrointestinal tract and penetrate into most organs and tissues of the body. Therapeutic concentrations are maintained for 12 hours. The active ingredients of Amoxytron chewable tablets are virtually not metabolized and are excreted from the body mainly with urine, and to a lesser extent with bile.

Indications:

Amoxytron chewable tablets is intended for the treatment of bacterial infectious diseases in dogs and cats, including:

- skin disorders (including deep and superficial pyoderma);

- urinary tract infections;

- bacterial respiratory infections (involving both upper and lower respiratory tract);

- bacterial enteritis, as well as bacterial infections, caused by pathogens sensitive to amoxicillin.

Contraindications:

Do not administer the drug to animals with hypersensitivity to beta-lactam antibiotics.

The drug can be used in pregnant and lactating animals under the supervision of a veterinarian.

The product is not intended for use in food-producing animals.

How to use:

The product is prescribed individually, orally. Amoxytron chewable tablets are administered to cats and dogs by hand or with a small amount of food (treats) during feeding or on the root of tongue using an introducer (tablet dispenser) immediately after feeding. Food intake does not affect the bioavailability of the active ingredients of the drug.

Single dose is 12.5 mg (according to the total amount of active ingredients) per 1 kg of animal bodyweight. Treatment regimen - twice a day.

Recommended doses of the drug product, depending on the animal bodyweight, are shown in the table below.

In difficult-to-treat diseases (respiratory infections), the dose of Amoxytron chewable tablets should be increased to 25 mg/kg of animal bodyweight twice a day.

Duration of treatment with Amoxytron chewable tablets is 5-7 days. In chronic or intractable diseases, especially deep pyoderma in dogs, treatment course can be 10-28 days.

Do not skip doses, as this may lead to a decrease in therapeutic effect. If one dose of the drug is missed, it should be administered as soon as possible. Further, continue the course of treatment at doses and according to the regimen provided for in the instructions.

Side effects:

When the drug is used in accordance with the instructions, the risk of side effects and complications is negligible. In case of allergic reactions, discontinue treatment with the drug and start antihistamines and, if necessary, symptomatic treatment.

Specific effects of Amoxytron chewable tablets at the start of treatment or at the end of the treatment course were not registered..

Overdose:

Signs of overdose have not been established.

Other drug interactions:

It is not recommended to co-administer the product with macrolides, tetracyclines, chloramphenicols and sulfonamides due to a possible decrease in the therapeutic effect of amoxicillin.

Storage conditions:

Store the product in a closed manufacturer's package, protected from direct sunlight, at 5°C to 25°C. Keep out of reach of children.

Shelf life of the drug when stored in a closed original package at the recommended conditions is 2 years from the date of manufacture. After the first opening of the bottle – not more than 1 month. Do not use after the expiry date.

Dosage form:

Polymer bottle, instructions for use.

Outer packaging: carton.